Eruptive nevi mimicking wart-like lesions under selective BRAF inhibition in a 37-year-old female melanoma patient

Case Reports in Dermatology

Volumn 5, Issue 1, 2013, Pages 69-72

  Schmitt, Laurenz ^a   Schumann, Tamara ^a   Inhoff, Oliver ^a   Löser, Christoph ^a   Rebel, Martin ^a   Dippel, Edgar ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

BRAF inhibitor; Eruptive nevi; Melanoma; Melanoma in situ; Side effects; Vemurafenib; Wart like lesions; Zelboraf

Indexed keywords

CORTICOSTEROID; VEMURAFENIB; B RAF KINASE;

ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; ERYTHEMA NODOSUM; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MELANOCYTIC NEVUS; METASTATIC MELANOMA; PRIORITY JOURNAL; RASH; SKIN DEFECT; TREATMENT DURATION; TREATMENT RESPONSE; WILD TYPE; CANCER CHEMOTHERAPY; CANCER SURGERY; DISEASE COURSE; DRUG ERUPTION; DRUG WITHDRAWAL; ENZYME INHIBITION; ERYTHEMA NODOSUM LIKE LESION; MELANOMA; MELANOMA IN SITU;

EID: 84877985163     PISSN: None     EISSN: 16626567     Source Type: Journal    
DOI: 10.1159/000350288     Document Type: Article

References (11)

1. Oberholzer PA, Kee D, Dziunycz P, et al: RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012;30:316-321.
2. Dummer R, Rinderknecht J, Goldinger SM: Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012;366:480-481.
3. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
4. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Eng J Med 2011;364:2507-2516.
5. Zimmer L, Hillen U, Livingstone E, et al: Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012;30:2375-2383.
6. Wellbrock C, Hurlstone A: BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010;80:561-567.
7. Haenssle HA, Kraus SL, Brehmer F, Kretschmer L, Völker B, Asper H, Kapp A, Gutzmer R: Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol 2012;148:1183-1185.
8. Bennani-Lahlou M, Mateus C, Escudier B, et al: Eruptive nevi associated with sorafenib treatment. Ann Dermatol Venereol 2008;135:672-674.
9. Arnault JP, Mateus C, Escudier B, et al: Skin tumors induced by sorafenib; paradoxical RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 2012;18:263-272.
10. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-430.
11. Ma L, Dominguez AR, Collins GR, Kia KF, Cockerell CJ: Hidradenitis Suppurativa, Eruptive Melanocytic Nevi, and Keratosis Pilaris-like Eruption in a Patient Treated With Vemurafenib. Arch Dermatol 2012;148:1428-1429.